Drug Trial Radar · NCT06128148
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
May 4, 2022
Primary completion
Jun 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Conditions
- Protein Kinase Inhibitors
- Other Protocol Specified Criteria
- Lung Neoplasms
- Brain Neoplasms
Interventions
JYP0322 50 mg qdDrug
JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 100 mg qdDrug
JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 200 mg qdDrug
JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 100 mg bidDrug
JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 150 mg bidDrug
JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 200 mg bidDrug
JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
JYP0322 150mg tidDrug
JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency and severity of adverse events of JYP0322Time frame: From the date of informed consent through 30 days after the last dose of study drug, approximately up to 36 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.